Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

Korecka JA, Thomas R, Christensen DP, Hinrich AJ, Ferrari EJ, Levy SA, Hastings ML, Hallett PJ, Isacson O.

Hum Mol Genet. 2019 Jul 1. pii: ddz126. doi: 10.1093/hmg/ddz126. [Epub ahead of print]

PMID:
31261377
2.

Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation.

Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, Moskites A, Atkinson E, Jodelka FM, Hinrich AJ, Hastings ML, Woolf CJ, Hallett PJ, Isacson O.

Stem Cell Reports. 2019 Jan 8;12(1):29-41. doi: 10.1016/j.stemcr.2018.11.021. Epub 2018 Dec 27.

3.

Small Scale Production of Recombinant Adeno-Associated Viral Vectors for Gene Delivery to the Nervous System.

Verhaagen J, Hobo B, Ehlert EME, Eggers R, Korecka JA, Hoyng SA, Attwell CL, Harvey AR, Mason MRJ.

Methods Mol Biol. 2018;1715:3-17. doi: 10.1007/978-1-4939-7522-8_1.

PMID:
29188502
4.

Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.

Korecka JA, Moloney EB, Eggers R, Hobo B, Scheffer S, Ras-Verloop N, Pasterkamp RJ, Swaab DF, Smit AB, van Kesteren RE, Bossers K, Verhaagen J.

J Neurosci. 2017 Sep 27;37(39):9361-9379. doi: 10.1523/JNEUROSCI.0084-17.2017. Epub 2017 Aug 21.

5.

In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells.

Korecka JA, Levy S, Isacson O.

Mol Cell Neurosci. 2016 Jun;73:3-12. doi: 10.1016/j.mcn.2015.12.004. Epub 2015 Dec 10. Review.

6.

Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling.

Korecka JA, van Kesteren RE, Blaas E, Spitzer SO, Kamstra JH, Smit AB, Swaab DF, Verhaagen J, Bossers K.

PLoS One. 2013 May 28;8(5):e63862. doi: 10.1371/journal.pone.0063862. Print 2013.

7.

Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.

Korecka JA, Eggers R, Swaab DF, Bossers K, Verhaagen J.

Restor Neurol Neurosci. 2013;31(2):155-67. doi: 10.3233/RNN-110222.

PMID:
23271419
8.

The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain.

van den Berge SA, van Strien ME, Korecka JA, Dijkstra AA, Sluijs JA, Kooijman L, Eggers R, De Filippis L, Vescovi AL, Verhaagen J, van de Berg WD, Hol EM.

Brain. 2011 Nov;134(Pt 11):3249-63. doi: 10.1093/brain/awr256.

PMID:
22075520
9.

Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.

Korecka JA, Verhaagen J, Hol EM.

Regen Med. 2007 Jul;2(4):425-46. Review.

PMID:
17635050

Supplemental Content

Loading ...
Support Center